Frequent alteration of p63 expression in human primary bladder carcinomas

Cancer Research

Volumn 60, Issue 13, 2000, Pages 3370-3374

  Park, Bum Joon ^a   Lee, Seung Jae ^a   Kim, Jin Il ^a   Lee, Sun Ju ^a   Lee, Choong Hyun ^a   Chang, Sung Goo ^a   Park, Jae Hoon ^a   Chi, Sung Gil ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER STAGING; DNA METHYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MULTIGENE FAMILY; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA-BINDING PROTEINS; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; MUTATION; PHOSPHOPROTEINS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 0034234312     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
2. Levin, A. J. The tumor suppressor genes. Annu. Rev. Biochem., 62: 623-651, 1993.
3. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J-C., Valent, A., Minty, A., Chalon, P., Lelias, J-M., Dumont, X., Ferrara, P., McKeon, F., and Caput, D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90: 809-819, 1997.
4. Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dotsch, V., Andrews, N. C., Caput, D., and McKeon, F. P63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell, 2: 305-316, 1998
5. Trink, B., Okami, K., Wu. L., Sriuranpong, J., Jen, J., and Sidransky, D. A new human p53 homologue. Nat. Med., 4: 747-748, 1998.
6. Osada, M., Ohba, M., Kawahara, C., Ishioka, C., Kanamaru, R., Katoh, I., Ikawa, Y., Nimura, Y., Nakagawara, A., Obinata, M., and Ikawa, S. Cloning and functional analysis of human p51. which structurally and functionally resembles p53. Nat. Med., 4: 839-843, 1993
7. Senoo, M., Seki, N., Ohira, M., Sugano, S., Watanabe, M., Tachibana, M., Tanaka, T., Shinkai, Y., and Kato, H. A second p53-related protein, p73L, with high homology to p73. Biochem. Biophys. Res. Commun., 248: 603-607, 1998.
8. Augustin, M., Bamberger, C., Paul, D., and Schmale, H. Cloning and chromosomal mapping of the human p53-related KET gene to chromosoe 3q27 and its murine homolog Ket to mouse chromosome 16. Mamm. Genome, 9: 899-902, 1998.
9. Jost, C. A., Marin, M. C., and Kaelin W. G., Jr. p73 is a human p53-related protein that can induce apoptosis. Nature (Lond.), 389: 191-194, 1997.
10. Corn, P. G., Kuerbitz, S. J., van Noesel, M. M., Esteller, M., Compitello, N., Baylin, S. B., and Herman, J. G. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′CpG island methylation. Cancer Res., 59: 3352-3356, 1999.
11. Kawano, S., Miller, C. W., Gombart, A. F., Bartram, C. R., Matsuo, Y., Asou, H., Sakashita, A., Said, J., Tatsumi, E., and Koeffler, H. P. Loss of p73 gene expression in leukemia/lymphomas due to hypermethylation. Blood, 94: 1113-1120, 1999.
12. Mai, M., Yokomizo, A., Qian, C., Yang, P., Tindall, D. J., Smith, D. I., and Liu, W. Activation of p73 silent allele in lung cancer. Cancer Res., 58: 2347-2349, 1998.
13. Takahashi, H., Ichimiya, S., Nimura, Y., Watanabe, M., Furusato, M., Wakui, S., Yatani, R., Aizawa, S., and Nakagawara, A. Mutation, allelotyping and transcription analysis of the p73 gene in prostatic carcinoma. Cancer Res., 58: 2076-2077, 1998.
14. Chi, S. G., Chang, S. G., Lee, S. J., Lee, C. H., Kim, J. I., and Park, J. H. Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Res., 59: 2791-2793, 1999.
15. Hagiwara, K., McMenamin, M. G., Miura, K., and Harris, C. C. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res., 59: 4165-4169, 1999.
16. Sunahara, M., Shishikura, T., Takahashi, M., Todo, S., Yamamoto, N., Kimura, H., Kato, S., Ishioka, C., Ikawa, Y., and Nakagawara, A. Mutational analysis of p51A/ TAp63γ, a p53 homolog, in non-small cell lung cancer and breast cancer, Oncogene, 18: 3761-3765, 1999.
17. Tani, M., Shimizu, K., Kawahara, C., Kohno, T., Ishimoto, O., Ikawa, S., and Yokota, J. Mutation and expression of the p51 gene in human lung cancer. Neoplasia, 1: 71-79, 1999.
18. Nishi, H., Isaka, K., Sagawa, Y., Usuda, S., Fujito, A., Ito, H., Senoo, M., Kato, H., and Takayama, M. Mutation and transcription analyses of the p63 gene in cervical carcinoma. Int. J. Oncol., 15: 1149-1153, 1999.
19. Parsa, R., Yang, A., McKeon, F., and Green, H. Association of p63 with proliferative potential in normal and neoplastic human kcratinocytes. J. Invest. Dermatol., 113: 1099-1105, 1999.
20. Li, M., Zhang, Z. F., Reuter, V. E., and Cordon-Cardo, C. Chromosome 3 allelic losses and microsatellite alterations in transitional cell carcinoma of the urinary bladder. Am. J. Pathol., 149: 229-235, 1996.
21. Koo, S. H., Kwon, K. C., Ihm, C. H., Jeon, Y. M., Park, J. W., and Sul, C. K. Detection of genetic alteralions in bladder tumors by comparative genomic hybridization and cytogenetic analysis. Cancer Genet. Cytogenet., 110: 87-93, 1999.
22. Chi, S. G., deVere White, R. W., Meyers. F. J., Siders, D., Lee, F., and Gumerlock, P. H. p53 in prostate: frequent expressed transition mutations. J. Natl. Cancer Inst., 86: 926-933, 1994.
23. Gumerlock, P. H., Chi, S. G., Shi, X. B., Voeller, H. J., Jacobson, J. W., Gelmann, E. D., and deVere White, R. W. p53 abnormalities in primary prostate cancer: single-strand conformation polymorphism analysis of complementary DNA in comparison with genomic DNA. J. Natl. Cancer Inst., 89: 66-71, 1997.
24. Shimada, A., Kato, S., Enjo, K., Osada, M., Ikawa, Y., Kohno, K., Obinata, M., Kanamaru, R., Ikawa, S., and Ishioka, C. The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. Cancer Res., 59: 2781-2786, 1999.
25. Kato, S., Shimada, A., Osada, M., Ikawa, S., Obinata, M., Nakagawara, A., Kanamaru, R., and Ishioka, C. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoter. Cancer Res., 59: 5908-5911, 1999.
26. Davison, T. S., Vagner, C., Kaghad, M., Ayed, A., Caput, D., and Arrowsmith, C. H. p73 and p63 are homoletramers capable of weak heterotypic interactions with each other but not with p53, J. Biol. Chem., 274: 18709-18714, 1999.
27. Roth, J., and Dobbelstein, M. Failure of viral oncoproteins to target the p53-homologue p51A. J. Gen. Virol., 80: 3251-3255, 1999.
28. Wienzek, S., Roth, J., and Dobbelstein, M. EIB 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p5.3. J. Virol., 74: 193-202, 2000.